Welcome to our dedicated page for MapLight Therapeutics news (Ticker: MPLT), a resource for investors and traders seeking the latest updates and insights on MapLight Therapeutics stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect MapLight Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of MapLight Therapeutics's position in the market.
MapLight Therapeutics (Nasdaq: MPLT) reported third quarter 2025 results and program milestones on Dec 4, 2025. Key clinical timelines: ZEPHYR Phase 2 topline for ML-007C-MA in schizophrenia expected in H2 2026; VISTA Phase 2 topline for Alzheimer’s disease psychosis expected in H2 2027; IRIS Phase 2 topline for ML-004 in ASD expected in H2 2026. The company completed enrollment in IRIS (~160 participants) and nominated ML-009 for IND-enabling studies; ML-021 IND-enabling studies expected complete H2 2026. Financing: completed an IPO and private placement in Oct 2025 raising $296.5 million gross ($269.8 million net). Cash, cash equivalents and short-term investments were $227.2 million at quarter end, expected to fund operations through 2027.
MapLight Therapeutics (NASDAQ:MPLT) closed its initial public offering on Oct 29, 2025, selling 16,962,500 shares at $17.00 per share, which includes the underwriters' full exercise of an option to purchase an additional 2,212,500 shares.
MapLight also completed a concurrent private placement of 476,707 shares at the IPO price to affiliates of Goldman Sachs. Gross proceeds to MapLight from the IPO and private placement, before underwriting discounts, commissions and offering expenses, were $296.3 million. All shares were offered by MapLight and began trading on the Nasdaq Global Select Market on Oct 27, 2025 under the symbol MPLT. The registration statement became effective on Oct 25, 2025.
MapLight Therapeutics (NASDAQ: MPLT) priced its initial public offering of 14,750,000 shares at $17.00 per share and granted underwriters a 30-day option to buy up to 2,212,500 additional shares.
The company also announced a concurrent private placement of 476,707 shares to affiliates of Goldman Sachs at the IPO price. Gross proceeds from the IPO and private placement are expected to be approximately $258.9 million before underwriting discounts, commissions, and expenses. Shares are expected to begin trading on the Nasdaq Global Market on October 27, 2025 under symbol MPLT, with the offering expected to close on October 28, 2025 subject to customary closing conditions.
FAQ
What is the current stock price of MapLight Therapeutics (MPLT)?
What is the market cap of MapLight Therapeutics (MPLT)?
